Chongqing Pharscin Pharmaceutical Co Ltd (002907) — Capital Reinvestment Ratio

Latest as of September 2025: 5.05x

Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a Capital Reinvestment Ratio of 5.05x as of September 2025, meaning it reinvests 5% of its operating cash flow (CN¥833.94K) in capital expenditures (CN¥4.21 Million). Check tangible equity quality of Chongqing Pharscin Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

5.05x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥833.94K
CNY

Capital Expenditures

CN¥4.21 Million
CNY

Data as of

Sep 2025
Most recent filing

Chongqing Pharscin Pharmaceutical Co Ltd Capital Reinvestment Ratio (2013–2024)

This chart tracks Chongqing Pharscin Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Chongqing Pharscin Pharmaceutical Co Ltd.

Annual Capital Reinvestment Ratio for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)

Year-by-year Capital Reinvestment Ratio for Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. See 002907 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 0.10x CN¥161.77 Million CN¥16.15 Million ▼ -76.4%
2023 0.42x CN¥219.34 Million CN¥92.82 Million ▼ -90.9%
2022 4.65x CN¥13.04 Million CN¥60.62 Million ▲ +579.7%
2021 0.68x CN¥82.85 Million CN¥56.64 Million ▲ +66.4%
2020 0.41x CN¥113.64 Million CN¥46.69 Million ▼ -58.1%
2019 0.98x CN¥65.92 Million CN¥64.66 Million ▼ -14.1%
2018 1.14x CN¥31.80 Million CN¥36.30 Million ▲ +121.8%
2017 0.51x CN¥81.34 Million CN¥41.87 Million ▲ +78.1%
2016 0.29x CN¥57.73 Million CN¥16.69 Million ▲ +18.0%
2015 0.25x CN¥66.10 Million CN¥16.20 Million ▼ -64.1%
2014 0.68x CN¥20.22 Million CN¥13.79 Million ▲ +69.3%
2013 0.40x CN¥47.34 Million CN¥19.06 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow